Menu
Currency
GWAS Study

Genome-wide meta-analysis identifies a novel susceptibility signal at CACNA2D3 for nicotine dependence.

Yin X, Bizon C, Tilson J et al.

28440896 PubMed ID
GWAS Study Type
18082 Participants
78 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

YX
Yin X
BC
Bizon C
TJ
Tilson J
LY
Lin Y
GI
Gizer IR
EC
Ehlers CL
WK
Wilhelmsen KC
Chapter II

Abstract

Summary of the research findings

Nicotine dependence (ND) has a reported heritability of 40-70%. Low-coverage whole-genome sequencing was conducted in 1,889 samples from the UCSF Family study. Linear mixed models were used to conduct genome-wide association (GWA) tests of ND in this and five cohorts obtained from the database of Genotypes and Phenotypes. Fixed-effect meta-analysis was carried out separately for European (n = 14,713) and African (n = 3,369) participants, and then in a combined analysis of both ancestral groups. The meta-analysis of African participants identified a significant and novel susceptibility signal (rs56247223; p = 4.11 × 10-8 ). Data from the Genotype-Tissue Expression (GTEx) study suggested the protective allele is associated with reduced mRNA expression of CACNA2D3 in three human brain tissues (p < 4.94 × 10-2 ). Sequence data from the UCSF Family study suggested that a rare nonsynonymous variant in this gene conferred increased risk for ND (p = 0.01) providing further support for CACNA2D3 involvement in ND. Suggestive associations were observed in six additional regions in both European and merged populations (p < 5.00 × 10-6 ). The top variants were found to regulate mRNA expression levels of genes in human brains using GTEx data (p < 0.05): HAX1 and CHRNB2 (rs1760803), ADAMTSL1 (rs17198023), PEX2 (rs12680810), GLIS3 (rs12348139), non-coding RNA for LINC00476 (rs10759883), and GABBR1 (rs56020557 and rs62392942). A gene-based association test further supported the relation between GABBR1 and ND (p = 6.36 × 10-7 ). These findings will inform the biological mechanisms and development of therapeutic targets for ND.

7,297 European ancestry cases, 5,577 European ancestry controls, 918 European ancestry whole genome sequenced cases, 921 European ancestry whole genome sequenced controls, African American cases, 1,500 African American controls

Chapter III

Study Statistics

Key metrics and study information

18082
Total Participants
GWAS
Study Type
No
Replicated
African American or Afro-Caribbean, European
Ancestry
U.S.
Recruitment Country
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.